Opendata, web and dolomites

ImOPac SIGNED

GemciTest: An innovative In Vitro Diagnostic for the decision-making process of pancreatic cancer treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ImOPac project word cloud

Explore the words cloud of the ImOPac project. It provides you a very rough idea of what is the project "ImOPac" about.

discovery    80    choose    treatment    recommended    thanks    bioinformatics    51k    ductal    create    stratification    decisional    lack    adenocarcinoma    pharmacogenomics    transcriptomics    diagnostic    action    blood    limited    personalized    mortality    signature    2011    decision    always    effectiveness    treatments    11    diagnosis    medical    360    market    turnover    pancreatic    cancer    which    usa    surgical    science    150k    employees    metastatic    stage    toxicities    june    began    sme    forefront    invasive    biomarkers    difficulty    clinical    nearly    versus    2020    mention    patient    occurs    score    innovative    imopac    rate    diagnose    gemcitest    until    chemotherapy    genomics    foundation    2017    populations    biomarker    acobiom    data    innovation    dead    death    partly    34    countries    western    regimen    13    stratify    2024    gene    biotech    sas    expertise    french    profiles    pdac    opportunity    1999    95    incurable    4th    breast    patients    regimens    algorithm   

Project "ImOPac" data sheet

The following table provides information about the project.

Coordinator
ACOBIOM 

Organization address
address: 1682 RUE DE LA VALSIERE CAP DELTA ZAC EUROMEDECINE II
city: GRABELS
postcode: 34790
website: www.acobiom.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACOBIOM FR (GRABELS) coordinator 50˙000.00

Map

 Project objective

Acobiom is a French Biotech SME (SAS, 8 employees). Since its foundation, June 1999, Acobiom has always been at the forefront of medical innovation, in particular in biomarker discovery and diagnostic development, thanks to its expertise and knowledge in genomics, transcriptomics, bioinformatics, and data science.

In 2011, Acobiom began working to address the problem of pancreatic cancer.

Pancreatic cancer is currently the 4th leading cause of cancer death in Western Countries. If no action is taken, it will rise to be second in 2020. For nearly 80% of patients (~51K and ~150K in USA and EU patients in 2017), diagnosis occurs at an advanced, non-surgical stage, making them incurable. The high mortality rate, with more than 95% of patients dead at 5 years, versus 13% for breast cancer, is partly due to the difficulty to diagnose, but also because of the lack of stratification of patients and a limited choice for treatments in the current decision-making process.

There are currently three major chemotherapy regimens for the pancreatic cancer, and up until now, the decisional algorithm in metastatic pancreatic ductal adenocarcinoma (PDAC) management does not mention pharmacogenomics biomarkers, needed to stratify patient populations and to choose the best treatment with the best clinical effectiveness for a given patient. These regimens have very different toxicities profiles which factors in to which regimen is recommended.

Through ImOPac project, Acobiom aims to implement an innovative approach to improve personalized pancreatic cancer management in the decision-making process of PDAC, by using biomarkers to help in the patient stratification. This approach is the GemciTest, a non-invasive test based on an 11-gene blood signature score.

Thanks to this innovation, Acobiom has an opportunity to create an EU new market estimated at 360 M€, and leading to a 34 M€ turnover by 2024.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMOPAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMOPAC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

PAROST (2019)

Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.

Read More